With the advancement of high peptide specificity and MHC-restricted TCRm Abs screening and synthesis methods [30], a growing number of TCRm Abs targeting solid tumor neoantigens considered undrugneable and monoclonal Abs targeting solid tumor-associated antigens have been identified and used to synthesize BiTEs for anti-tumor immunity [122–124]. Here, HLA-C is linked to neoplasm.